LEUPRORELIN

leuprorelin acetate 45 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $1,377.51 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Lucrin Depot 6-Month
leuprorelin acetate 30 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Central precocious puberty
Treatment phase: Continuing treatment with this drug, or, switching gonadotropin releasing hormone analogue therapy
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 1 DPMQ: $714.05 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Lucrin Depot Paediatric 30 mg PDS
leuprorelin acetate 30 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Central precocious puberty
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 1 DPMQ: $714.05 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Lucrin Depot Paediatric 30 mg PDS
leuprorelin acetate 45 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Central precocious puberty
Treatment phase: Initial treatment

Restriction

Indication: Central precocious puberty
Treatment phase: Continuing treatment with this drug, or, switching gonadotropin releasing hormone analogue therapy
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $1,377.51 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Eligard 6 month
leuprorelin acetate 7.5 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $271.33 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Eligard 1 month
leuprorelin acetate 22.5 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 1 DPMQ: $714.89 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Eligard 3 month
leuprorelin acetate 30 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 1 DPMQ: $940.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Eligard 4 month
leuprorelin acetate 45 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $1,377.51 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Eligard 6 month
leuprorelin acetate 7.5 mg modified release injection [1 chamber] (&) inert substance diluent [1 mL chamber], 1 dual chamber syringe
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $271.33 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Lucrin Depot 7.5mg PDS
leuprorelin acetate 22.5 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe
Manner of administration:Injection
General Schedule
Restricted Benefit

Restriction

Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 1 DPMQ: $714.89 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Lucrin Depot 3 Month PDS